AyoxxA Biosystems Closes Series A Financing Round

COLOGNE, Germany, and SINGAPORE, September 20, 2012 /PRNewswire/ –

2.6 million Euro financing will accelerate development of cutting-edge technology for
protein analysis

AyoxxA Biosystems, an international biotechnology company, today announces it has
closed a 2.6 million Euro Series A financing round. The round was led by Wellington
Partners Venture Capital and included NRW.BANK, HTGF – High-Tech-Gruenderfonds, and
private investors, Rainer Christine and Dr. Gregor Siebenkotten, both formerly executive
board members and co-founders of amaxa biosystems.

The funds raised will be used to drive the further development of AyoxxA’s proprietary
platform technology and the scale-up of production of its novel bead-based biochips as the
company moves towards commercialization.

AyoxxA’s technology is aimed at transforming the throughput and accuracy of protein
analysis to deliver the analytical power now seen only for DNA arrays. The platform is
based around proprietary In-situ Encoded Bead-based Arrays (IEBA) which allow the
simultaneous measurement of multiple proteins from minute samples.

Unlike current bead-based microarrays, AyoxxA’s IEBA need no physical label to allow
multiplex analysis and thus hugely reduce the complexity of downstream analysis while
increasing the number of individual proteins that can be analysed at the same time. The
arrays are designed to be readily adaptable to standard high throughput screening systems
and offer the potential of tens of thousands of ELISA assays in a single well of a
biochip.

Dr. Andreas Schmidt, CEO of AyoxxA, said: “This fundraising provides Ayoxxa with the
resources to significantly accelerate the scale-up of production of our unique bead-based
biochips and, through the expansion of our base in Cologne, prepare to bring our
technology to market. We believe our technology can revolutionise protein analysis and
with our growing presence in Europe combined with our continued access to the world-class
science in Singapore we are uniquely positioned to deliver on that promise.”

Dr. Regina Hodits, General Partner of Wellington Partners Venture Capital, commented:
“AyoxxA’s technology has the potential to become the new standard for the precise, fast,
and cost effective analysis of multiple protein-protein interactions in limited sample
volumes. This will allow the company to initially address a research market worth hundreds
of millions of dollars and longer term reach into pharmaceutical screening and ultimately
diagnostics. In Andreas Schmidt and co-founder and CSO Dieter Trau, we have a very
entrepreneurial team which has already rapidly brought the AyoxxA technology from the idea
stage to first proof-of-concept. We look forward to working with the company as it builds
on this excellent foundation and delivers benefits to its customers and investors.”

Rainer Christine, Chairman of the Board of AyoxxA, said: “It is exciting to be
investing in AyoxxA at a critical point in the Company’s development. I have followed its
story closely since it was founded by Andreas and Dieter, who had invented the technology
as a Professor of Bioengineering at the National University of Singapore. I am impressed
by the progress made in advancing the technology and by the potential it has to address
significant markets. I hope to bring the experience I gained in successfully building
amaxa to the Board and Company as it grows.”

Dr. Matthias Dill, HTGF investment manager, added: “We are pleased to have played a
role in building a consortium of experienced investors to optimally support AyoxxA as it
benefits further from its position as part of two high tech countries. The company’s
choice to base its headquarters in Cologne highlights the continuing attractiveness of
Germany as a site for building new companies and growing international businesses.”

Following the fundraising, AyoxxA’s Board of Directors will comprise: Chairman Rainer
Christine; Board Members Regina Hodits, Matthias Dill and Aristotelis Nastos (NRW.BANK);
and Board Observers Lukas Guenther (Wellington Partners) and Florian Stinauer (NRW.BANK).

About AyoxxA

AyoxxA, an international biotech company based in Cologne, Germany, and Singapore, has
developed a proprietary technology platform for multiplexed protein analysis. Core to this
cutting-edge technology are “In-situ Encoded Bead-based Arrays” (IEBA) which allow
simultaneous, precise and cost effective protein analysis in very small sample volumes.

These novel biochips allow users to combine high throughput screening and multiplexed
assay formats at the same time and thus have the potential to revolutionize applications
in biomedical research, pharmacological screening, and diagnostics.

AyoxxA was founded as a spin-off of the National University of Singapore (NUS) in
2010. The company received multiple grants in Singapore from the National Research
Foundation (NRF), the SMART Innovation Centre (Singapore MIT Alliance for Research and
Technology), and SPRING’s Technology Enterprise Commercialisation Scheme (TECS). It
established corporate headquarters in Cologne in Spring 2012 and continues to run
operations in Singapore.

        Contacts

        Dr. Andreas Schmidt, CEO
        AyoxxA Biosystems GmbH
        BioCampus Cologne
        Nattermannallee 1
        50829 Koln, Germany
        Phone:+49(0)221-222529-0
        E-Mail: info@ayoxxa.com

http://www.ayoxxa.com

        AyoxxA Living Health Technologies Pte. Ltd National University of Singapore (NUS)
        Block E3A, #07-02, 7 Engineering Drive 1
        117576 Singapore
        Phone: +65-65166482

        Citigate Dewe Rogerson
        Chris Gardner/Nina Enegren
        Tel: +44(0)20-7638-9571
        nina.enegren@citigatedr.co.uk

SOURCE AyoxxA